CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向 HIV-1 储存库的 HIV-1 特异性嵌合抗原受体细胞研究进展
英文原题：Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir.
查看英文原题
Advances in HIV-1-specific chimeric antigen receptor cells to target the HIV-1 reservoir.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
针对HIV-1的抗逆转录病毒治疗（ART）显著改善了感染者结局，但需要终身依从用药，且可能带来短期和长期毒性。目前正在开展多项临床前和临床研究，开发无需ART即可通过免疫控制HIV-1的疗法。嵌合抗原受体（CAR）细胞疗法在血液系统恶性肿瘤中取得成功，重新推动了将CAR细胞用于增强抗HIV-1免疫、控制或清除病毒，以及实现停用ART后HIV-1缓解的研究。本文回顾最初临床试验开展以来二十年间抗HIV-1 CAR细胞疗法的改进，介绍为保护CAR细胞免受HIV-1感染所需的额外工程化，并概述正在推进至HIV-1临床试验的CAR细胞疗法现状。
展开英文摘要原文
Antiretroviral therapy (ART) for HIV-1 has dramatically improved outcomes for people living with HIV-1 but requires life-long adherence and can be associated with short and long-term toxicity. Numerous pre-clinical and clinical investigations are underway to develop therapies for immune control of HIV-1 in the absence of ART.
The success of chimeric antigen receptor (CAR) cell therapy for hematological malignancy has renewed efforts to develop and investigate CAR cells as strategies to enhance HIV-1 immunity, enable virus control or elimination, and allow ART-free HIV-1 remission.
Here, we review the improvements in anti-HIV-1 CAR cell therapy in the two decades since their initial clinical trials were conducted, describe the additional engineering required to protect CAR cells from HIV-1 infection, and preview the current landscape of CAR cell therapies advancing to HIV-1 clinical trials.
论文信息
- 作者
- Choudhary MC、Cyktor JC、Riddler SA
- 单位
- Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.United States
- 期刊
- Journal of virus eradication2022 Jun
- 原文标识
- PubMed 35784676 · DOI 10.1016/j.jve.2022.100073
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →